Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18232507 | 0.92 | L3MBTL1 (0.58) | L3MBTL1CHRM2MC4RMC5RMC3R | |
| SCHEMBL10045171 | 0.92 | L3MBTL1 (0.62) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL10045173 | 0.92 | L3MBTL1 (0.62) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL10045143 | 0.90 | L3MBTL1 (0.64) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL5792717 | 0.88 | L3MBTL1 (0.62) | L3MBTL1CHRM2MC4RMC5RMC3R | |
| SCHEMBL10045180 | 0.85 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL10045172 | 0.85 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL10045175 | 0.85 | L3MBTL1 (0.55) | L3MBTL1CHRM2SMN1; SMN2MCHR1HRH4 | |
| SCHEMBL10045072 | 0.85 | SMN1; SMN2 (0.65) | L3MBTL1CHRM2SMN1; SMN2HRH4HRH3 | |
| SCHEMBL15134858 | 0.84 | CHRM2 (0.61) | CHRM2MC4RMC5RMC3RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | UNIVERSITY OF CANBERRA (AU) | 2019-03-05 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | THE J. DAVID GLADSTONE INSTITUTES | 2012-05-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007021839-A2 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | L3MBTL1 209/4885CHRM2 3888/4885MC4R 4188/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | L3MBTL1 1360/4885CHRM2 1381/4885MC4R 4328/4885 |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | L3MBTL1 1472/4885CHRM2 4401/4885MC4R 4789/4885 |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | L3MBTL1 1472/4885CHRM2 4401/4885MC4R 4789/4885 |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | L3MBTL1 1472/4885CHRM2 4401/4885MC4R 4789/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | L3MBTL1 209/4885CHRM2 3888/4885MC4R 4188/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | L3MBTL1 964/4885CHRM2 2173/4885MC4R 1462/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | L3MBTL1 1360/4885CHRM2 1381/4885MC4R 4328/4885 |
| US-20120108500-A1 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription | KDM3B, DNMT3B, KDM1B | L3MBTL1 305/4885CHRM2 3669/4885MC4R 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.